New Delhi, April 3 -- Wockhardt Ltd that built its name as a maker of generic drugs is shifting its focus in the US market to developing new antibiotics, turning away from generics and entering a space largely vacated by Big Pharma in recent years.

The company is working on new antibiotics and has identified segments for a push into biosimilar drugs, chairman Habil Khorakiwala said, in the wake of promising results shown by Zaynich, an antibiotic it developed in-house. Wockhardt is in the process of seeking approvals from the US Food and Drug Administration (FDA) for the drug, at a time of rising drug resistance and few new antibiotics.

Also Read | This multi-billion dollar opportunity could be a game changer for Wockhardt

The company ...